How Can We Help?

Target even more respiratory pathogens at once—now including SARS-CoV-2

Upper and lower respiratory tract infections are caused by a broad range of microbes—including RNA and DNA viruses, bacteria, and even fungi—and yet are often symptomatically similar. Co-infections are a growing concern that require broad and effective pathogen detection, yet traditional detection methods, such as immunoassays and culture-based approaches, have limitations. While molecular testing is more sensitive, most
commercially available tests are expensive and primarily focus on either viruses or bacteria.

The Applied Biosystems™ TrueMark™ Respiratory Panel 2.0, TaqMan® Array Card* is a sensitive, syndromic panel–based real-time PCR solution for the detection of respiratory pathogens. Now with SARS-CoV-2 targets, this panel features the most markers of pathogenic organisms of any test on the market at the lowest cost per sample, to help you identify key respiratory infections and study SARS‑CoV‑2 co-infections quickly and cost-effectively.

Would you like early access to the new TrueMark Respiratory Panel 2.0, TaqMan Array Card prior to its official release?

Become an early adopter to gain access to the following features:
  • Extensive coverage including SARS-CoV-2 targets — with verified assays for 42 pathogen targets, our solution features the largest number of markers of pathogenic organisms of any test on the market
  • Cost-effective—lowest cost per sample when compared with other commercially available molecular solutions
  • Multiple sample input types—including nasopharyngeal (NP) swabs, bronchoalveolar lavage (BAL), and nasal aspirate